Table 3.

Compliance and persistence measures of users experienced to disease-modifying agents

	Fingolimod	Interferon beta-1b		Intramuscular interferon beta-1a		Subcutaneous interferon beta-1a		Glatiramer acetate
	N=152	N=35		N=66		N=98		N=115
			p-value		p-value		p-value		p-value
PDC: mean (SD)	0.83 (0.23)	0.61 (0.30)	0.0002	0.67 (0.32)	0.0004	0.68 (0.31)	0.0001	0.73 (0.30)	0.0040
PDC Categories (%)
0-<0.2	4.61	17.14	0.0009	9.09	0.0002	10.20	0.0002	6.09	0.0003
0.2-<0.4	3.95	8.57		22.73		11.22		11.30
0.4-<0.6	2.63	11.43		4.55		12.24		13.91
0.6-<0.8	15.13	22.86		10.61		18.37		7.83
0.8-1	73.68	40.00		53.03		47.96		60.87
MPR: mean (SD)	0.92 (0.08)	0.82 (0.18)	0.0066	0.88 (0.13)	0.0287	0.84 (0.19)	0.0004	0.89 (0.16)	0.0602
MPR Categories (%)			0.0001		0.0069		0.0004		0.0106
0-<0.2	0.00	0.00		0.00		1.10		0.93
0.2-<0.4	0.00	3.33		0.00		3.30		1.85
0.4-<0.6	0.00	10.00		5.00		5.49		5.56
0.6-<0.8	9.52	16.67		16.67		18.68		6.48
0.8-1	90.48	70.00		78.33		71.43		85.19
Persistence (<60 day gap) (%)	74.34	42.86	0.0003	53.03	0.0020	54.08	0.0009	62.61	0.0396
Persistent days (days till first 60-day gap) (%)
No gap	74.34	42.86		53.03		54.08		62.61
1-90	6.58	22.86		15.15		19.39		12.17
91-180	4.61	5.71		21.21		10.20		13.91
181-270	9.21	17.14		6.06		10.20		6.96
270+	5.26	11.43		4.55		6.12		4.35
Switched to other DMTs after discontinuation (%)	4.61	11.43	0.1219	13.64	0.0188	9.18	0.1488	13.04	0.0130

P-values based on comparison with fingolimod cohort, using Chi-square tests for categorical variables and Student’s t-tests for continuous variables.

DMT: disease-modifying therapy. SD: standard deviation. PDC: proportion of days covered. MPR: medication procession ratio.